



CDMSO

One-stop Integrated Solution

Enhancing the Advancement of Biologics Drug Development

Leading Biologics CDMSO

Founded in 2016, Canton biologics is a one-stop international CDMSO company that focuses on providing bio-pharmaceutical development, manufacturing, and supply chain services for global innovative pharmaceutical enterprises. With excellent technology and reliable delivery, we accelerate the high-quality research and development of biologics for partners, reduce costs, and benefit public health and life.

We have five R&D Manufacture centers in China and own a team of more than 300 scientists with over 15 years of pharmaceutical experience. Furthermore, over 60% of our researchers and developers are masters and doctors. As a highly efficient company, we have created a new record that from DNA to CMC in only 7 months, which has played an important role in the rapid advancement of customers' products to clinical practice. In addition, we have 13+5 manufacturing lines complying with China, US and EU GMP standard (50-2000L, batch, fed-batch, perfusion) for DS and DP manufacturing.

Shanghai R&D + MFG center Global Clinical Service Center (Shanghai Biologics 200L-2000L)







Five sites in China 300+ employees

International Partnering

Global license in and out International tech-transfer

Versatile platforms

Expertise in Cell line, Vector, Media for complex protein

CLD-2GMP in 7.5 months







High efficiency in delivery

Bethlehem R&D Center

(Guangzhou - Biologics)









CanCelltech MFG Site

(Guangzhou - CGT)



Kunlun MFG Site (Foshan Biologics 50-2000LGMP)



One-stop Service Platform Expediting your molecule from early stage to commercialization

Tech & Capacity

- Leading End-to-End Biologics CMC platform, including Antibody Optimization, Cell Line and Process Development, Physiochemical, Biochemical, Characterization, Tech-Transfer, and Clinical Bioanalysis
- 13+5 manufacturing lines complying with China, US and EU GMP standard, 50-2000L (batch, fed-batch, perfusion) DS and DP manufacturing





Service Offerings

- Biologics CDMO, covering Monoclonal Antibody, Bispecific Antibody, Fusion Protein, Recombinant Protein, Vaccine
- Cell and Gene Therapy (CGT) CDMO
- Global Clinical Supply manufacturing, packaging, storage, distribution



Development

Proprietary Cell Lines-owns full commercial license

CHOzen[®] (CHO-K1), CHOExpress[®] High-producing CHO host cell line

O CHOFlow[®] Fucosyltransferase 8 knock out CHO line, enhanced ADCC effect.

CHO GSKO Glutamine synthetase knockout cell lines, no need to add MSX during screening

● GLYCOEXPRESS [®] (GEX[®]) For expression of complex proteins, viruses, specially tailored proteins. Human cell lines are required for different glycosylation and modification.

Canvector[®]-High Expression Vector Series



We offer an extensive upstream and downstream process development expertise shaped by multidisciplinary projects, including mAb, BsAb, recombinant/fusion proteins, vaccines, coagulation factors, growth factors, exosomes. CBoost[®] process increases titer by 50%-200%, and 22 g/L is achieved in mAb molecule.

Flexible Cell Culture Platform

Host Cell: CHO, GEX, HEK, SP2/0, Hybridoma **Process: Perfusion, Fed-batch, Intensified Fed-batch**



Complete process development up to 15 L in 4 months

We offer 50L/200L/500L manufacturing services to support Tox, IND submission and clinical trial batches domestically and globally. Multiple batches can be handled simultaneously and disposable systems have been applied to minimize the risk of cross-contamination and allow rapid replacement.

Our commercial manufacturing team has >10 years of GMP manufacturing experiences and strong track record in tech transfer and manufacturing for several commercially launched innovative and biosimilar biologics within and outside China.

Flexible facilities



MSAT Platform

to MF, or between different MF sites.



Manufacturing

Aseptic fill/finish

Various formulation development platforms



Lyophilization



High concentration





Inhalation



Nasal spray



Fill & Finish Capacity

Sterile vials production line



- Compatible with 2R, 6R, 8R, 10R, 14R, 20R, 50R penicillin vials Automatic filling production line with isolator system, ensure good levels of sterility and particle control
- Filling speed up to 15,000 vials per hour

Sterile pre-filled syringe production line



- Compatible with 1ml standard, 1ml slender, 3ml pre-filled syringes Automatic pre-filled syringe filling production line with isolator system ,
- ensure good levels of sterility and particle control
- Filling speed up to 8,000 syringes per hour

Nasal spray/ throat spray line



- Compatible with 2R, 6R, 8R, 10R, 14R, 20R, 50R penicillin vials • Automatic filling production line with isolator system, ensure good levels of sterility and particle control
- Adding Spray cap speed up to 6,000 bottles per hour

Analytical Method Development

We understand the importance of a well-planned strategy that combines sensitive, specific, and qualified analytical assays to assist development decisions in bringing a promising drug candidate to market. Therefore, Canton Biologics is well-equipped with leading-edge technologies, state-of-the-art techniques and highly trained scientists to support a plethora of analytical services, offering solutions to support every phase of drug discovery and development.

- · Exosomes
- Concentration
- Purity and impurities
- · Glycan and post-translational modifications
- · Primary and higher-order structure
- · Cell-based potency
- Binding potency

We provides efficient and specialized registration support, including domestic and foreign IND (CTA)/BLA(MAA)/conversion and other declaration services. Our registration and regulatory team has rich experience in US and European registration filings, fully understands the laws and regulations and communication mechanisms of various regulatory agencies and can comprehensively provide support strategy and planning for CMC, preclinical, and clinical study design for customers throughout the life cycle of drug development.



- solving problems in R&D and filing process;
- development of registration and declaration strategy;

- · Affinity analysis
- Biomarkers for CGT and exosome
- · Gene analysis

- · Residual analysis
- · Safety analysis
- Product characterization

Regulatory Support

• Experience: rich domestic and international former FDA CMC professionals and industry operators, dozens of domestic and international successful filing experience;

• **Technology:** proficient in domestic and international regulations and guidelines, effectively

• Efficient: standardised registration and declaration service process, accurate and fast

Clinical Supply Best Solution of Quality, Speed and Cost

Global Supply Center

Your Well managed Global Clinical Supply Network



Shanghai Free Trade Zone main facility China and Global Supply 6,000m² Building

Clinical Service Mgt

- Design Clinical Pack and Kit based on the Clinical Trial protocol
- Plan the packaging Campaign based on study parameters
- IRT initial setup and ongoing update
- Act as unblind person
- Training

Storage & Distribution

- Clinical storage for various temperature ranges
- Distribution clinical sites
- International depot and distribution network
- Specialty & Cold Chain handling

Manufacturing & Packaging

- Primary packaging for chemical and biological products
- Secondary packaging based on the Pack and Kit design of the clinical study
- Labelling for blind and open studies
- Commercial Packaging

Comparator Sourcing

- Consulting for China and global commercial drug sourcing

- Ancillary sourcing
- Sourcing of Medical Devices
- Other equipment for CT

- Comparator sourcing
- Chemo drug sourcing

Canton Biologics is an international, technology-driven, biologics CDMSO, fully dedicated to offer comprehensive biologics development and manufacturing services for our clients.

Accumulated Project No.



Case Study: Biosimilar

Experience on Biosimilar

- Format type
 - mAb lgG
 - Fc-fusion protein

Fast development timeline

Biosimilar development platform 16 to 18 months from DNA to IND

Project	Format	CLD	PD	МСВ	Tox batch	GMP batch	IND
C1	mAb IgG						
C2	Fc-fusion						
C3	Fc-fusion						







	High Titer/ Yield/ Purity
	Titer
	>6 g/L (after Process developoment)
	Yield
	35 to 80 %(Depends on formats)
	Purity
n	SEC>99%

Empower Future with Biotechnology

For innovative development need and high quality of life, to create value for human and society

- Recombinant Protein
- Plasmid/Viral Vector

Probiotics

Fusion Protein